China, India drugmakers must be cutting corners, says Teva Europe CEO; FDA finds fake Tamiflu via the Internet;

> Teva Europe's CEO Gerald Van Odijk says he wants regulators to conduct dawn raids on pharma plants in India and China because price analyses show that drugmakers there must be cutting corners. Article

> The FDA is warning consumers about Generic Tamiflu, sold over the Internet, which contains none of the real McCoy's active ingredient but instead a penicillin-like antibiotic. Article

> Swiss-based API maker Siegfried USA broke ground last week for a $1.5 million, 7,000-square-foot warehouse at its manufacturing plant in Pennsville Township, NJ. Article

> VeriPac 455 is a non-destructive inspection system for micro leak detection of empty and pre-filled syringes. Item

> TCP Reliable has set up a business unit to provide regulatory and cold chain compliance products to the US market. Release

Suggested Articles

Fujifilm Diosynth Biotechnologies last year committed 10 billion yen toward its manufacturing operations. It has now kicked off one of those projects.

Popular logic says you never switch horses, or CDMOs, in the middle of the stream, but Acacia Pharma had to do that to win an FDA approval.

The FDA has found issues with the testing practices of a U.S. generics maker that had specific problems with ADHD and weight-loss drugs.